肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

阿斯利康旗下三个靶向肿瘤药物进入III期临床试验

2013-05-23 佚名 dxy

肿瘤药物非小细胞肺癌阿斯利康临床试验
关注

阿斯利康近日曾强调肿瘤药物是其药物研发的核心领域，该公司目前正推进三个肿瘤药物进入III临床试验。 首先，阿斯利康生物制剂研发部门的医学免疫公司已为Moxetumomab pasudotox的后期研究招募到首位患者。这项试验研究由美国国家癌症研究所(NCI)的癌症治疗评价计划主办，将评价CD22抗毒素作为一种潜在治疗药物用于对标准疗法无响应或标准治疗后复发的毛细胞白血病成人患者的治疗效果。 阿

阿斯利康近日曾强调肿瘤药物是其药物研发的核心领域，该公司目前正推进三个肿瘤药物进入III临床试验。

首先，阿斯利康生物制剂研发部门的医学免疫公司已为Moxetumomab pasudotox的后期研究招募到首位患者。这项试验研究由美国国家癌症研究所(NCI)的癌症治疗评价计划主办，将评价CD22抗毒素作为一种潜在治疗药物用于对标准疗法无响应或标准治疗后复发的毛细胞白血病成人患者的治疗效果。

阿斯利康同时也表示公司正计划于2013年下半年开展聚腺苷二磷酸-核糖聚合酶（PARP）抑制剂奥拉帕尼（Olaparib）的III临床试验。这将在II期临床试验之后紧接着进行，II期临床试验数据一两个星期内将在芝加哥召开的美国临床肿瘤学协会会议上发布，试验数据证实了奥拉帕尼作为一种维持治疗药物用于BRCA基因突变的铂敏感复发性乳腺癌患者的治疗潜力。

Selumetinib的临床研究数据也将在美国临床肿瘤学协会会议上发布，这款药物是一种用于治疗黑色素瘤的选择性MEK激酶抑制剂，其III临床研究不久后将开展，III临床研究中Selumetinib将与多西他赛合并用药作为二线治疗药物用于治疗KRAS基因突变呈阳性和转移性非小细胞肺癌患者。

阿斯利康创新药物与早期开发的主管Menelas Pangalos说，“癌症是我们三大核心治疗药物研发领域之一，我们正对奥拉帕尼和Selumetinib取得进步，结合我们在小分子和生物制剂领域更广泛的早期投资组合，使我们在加强肿瘤靶点药物研发线上占据了一个有力的位置。”

AZ puts three targeted cancer drugs into Phase III
Having recently stressed that oncology is a core therapy area for its research, AstraZeneca is moving three of its cancer compounds into Phase III trials.
First up, MedImmune, AstraZeneca’s biologics R&D arm, has enrolled the first patient in a late-stage study of moxetumomab pasudotox. It is sponsored by the Cancer Therapy Evaluation Program at the US National Cancer Institute (NCI), and will evaluate the CD22 immunotoxin as a potential treatment in adults with hairy cell leukaemia who have not responded to or relapsed after standard therapy...

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jan 06 04:08:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652693, encodeId=46011652693a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jan 08 11:08:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931405, encodeId=babf193140517, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Apr 02 01:08:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915772, encodeId=ed361915e72b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 16 07:08:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446741, encodeId=fc821446e414e, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524536, encodeId=fb6b152453615, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537655, encodeId=6083153e655fb, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594325, encodeId=0c1f1594325e8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2014-01-06 839640778

    #I期临床试验#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jan 06 04:08:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652693, encodeId=46011652693a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jan 08 11:08:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931405, encodeId=babf193140517, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Apr 02 01:08:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915772, encodeId=ed361915e72b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 16 07:08:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446741, encodeId=fc821446e414e, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524536, encodeId=fb6b152453615, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537655, encodeId=6083153e655fb, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594325, encodeId=0c1f1594325e8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2014-01-08 医生2402

    #I期临床#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jan 06 04:08:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652693, encodeId=46011652693a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jan 08 11:08:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931405, encodeId=babf193140517, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Apr 02 01:08:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915772, encodeId=ed361915e72b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 16 07:08:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446741, encodeId=fc821446e414e, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524536, encodeId=fb6b152453615, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537655, encodeId=6083153e655fb, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594325, encodeId=0c1f1594325e8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2014-04-02 kksonne

    #II期临床试验#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jan 06 04:08:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652693, encodeId=46011652693a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jan 08 11:08:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931405, encodeId=babf193140517, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Apr 02 01:08:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915772, encodeId=ed361915e72b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 16 07:08:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446741, encodeId=fc821446e414e, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524536, encodeId=fb6b152453615, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537655, encodeId=6083153e655fb, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594325, encodeId=0c1f1594325e8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2014-04-16 juliusluan78

    #III#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jan 06 04:08:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652693, encodeId=46011652693a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jan 08 11:08:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931405, encodeId=babf193140517, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Apr 02 01:08:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915772, encodeId=ed361915e72b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 16 07:08:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446741, encodeId=fc821446e414e, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524536, encodeId=fb6b152453615, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537655, encodeId=6083153e655fb, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594325, encodeId=0c1f1594325e8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2013-05-25 smartjoy

    #肿瘤药物#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jan 06 04:08:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652693, encodeId=46011652693a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jan 08 11:08:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931405, encodeId=babf193140517, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Apr 02 01:08:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915772, encodeId=ed361915e72b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 16 07:08:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446741, encodeId=fc821446e414e, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524536, encodeId=fb6b152453615, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537655, encodeId=6083153e655fb, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594325, encodeId=0c1f1594325e8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2013-05-25 guihongzh

    #II期临床#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jan 06 04:08:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652693, encodeId=46011652693a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jan 08 11:08:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931405, encodeId=babf193140517, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Apr 02 01:08:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915772, encodeId=ed361915e72b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 16 07:08:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446741, encodeId=fc821446e414e, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524536, encodeId=fb6b152453615, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537655, encodeId=6083153e655fb, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594325, encodeId=0c1f1594325e8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2013-05-25 柳叶一刀

    #肿瘤药#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jan 06 04:08:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652693, encodeId=46011652693a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jan 08 11:08:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931405, encodeId=babf193140517, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Apr 02 01:08:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915772, encodeId=ed361915e72b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 16 07:08:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446741, encodeId=fc821446e414e, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524536, encodeId=fb6b152453615, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537655, encodeId=6083153e655fb, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594325, encodeId=0c1f1594325e8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2013-05-25 guihongzh

    #III期临床试验#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jan 06 04:08:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652693, encodeId=46011652693a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jan 08 11:08:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931405, encodeId=babf193140517, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Apr 02 01:08:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915772, encodeId=ed361915e72b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 16 07:08:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446741, encodeId=fc821446e414e, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524536, encodeId=fb6b152453615, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537655, encodeId=6083153e655fb, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587991, encodeId=4468158e9916b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594325, encodeId=0c1f1594325e8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat May 25 09:08:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2013-05-25 智智灵药

    #III期#

    0

相关资讯

肿瘤防治宣传周：肿瘤药物治疗面临选择困境

       当肿瘤来袭，患者和医生面临很多选择，而作出正确的选择往往很难。采访中，一位专家告诉记者，当前肿瘤患者及医生所面临的选择困境，与医疗政策、法律支持、社会诚信、医患关系、舆论引导等外界环境息息相关。  　　困境一  　　医保政策与医患期望差距大  　　张先生的母亲因为Ⅱ期非小细胞肺癌刚刚接受左肺叶切除